MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Biological and Clinical Manifestations of Huntington’s disease in Gene Carriers Very Far from Predicted Onset: The Young Adult Study

P. Zeun, R. Scahill, K. Osborne-Crowley, E. Johnson, S. Gregory, C. Parker, J. Lowe, A. Nair, C. O'Callaghan, C. Langley, M. Papoutsi, P. McColgan, C. Estevez-Fraga, K. Fayer, H. Wellington, F. Rodrigues, L. Byrne, A. Heselgrave, H. Hyare, C. Sampaio, H. Zetterberg, H. Zhang, E. Wild, G. Rees, T. Robbins, B. Sahakian, D. Langbehn, S. Tabrizi (London, United Kingdom)

Meeting: MDS Virtual Congress 2020

Abstract Number: 267

Keywords: Chorea (also see specific diagnoses, Huntingtons disease, etc): Clinical features, Chorea (also see specific diagnoses, Huntingtons disease, etc): Etiology and Pathogenesis, Chorea (also see specific diagnoses, Huntingtons disease, etc): Treatment

Category: Huntington's Disease

Objective: To perform a deep phenotyping of a Huntington’s Disease (HD) cohort further from onset than previously studied to establish when disease related markers first become detectable and the best measures that may be used as endpoints in future trials in early premanifest HD.

Background: Crucial to the future success of disease modifying treatments for Huntington’s disease is identifying a timepoint where there are measurable biomarkers of early neurodegeneration without detectable changes in clinical function. We aimed to identify this timepoint and the best measures that may be used for endpoints for future therapeutic trials.

Method: HD-YAS (the Young Adult Study) recruited 64 young adult preHD, approximately 24 years from predicted clinical onset, and 67 matched controls. All participants underwent detailed cognitive and neuropsychiatric assessments, multi-modal imaging and collection of blood and cerebrospinal fluid (CSF). A cross-sectional analysis was performed using general least-squares linear models to evaluate group differences.

Results: We found no significant evidence of cognitive or psychiatric impairment in our cohort of preHD ~24 years from predicted onset (minimum False Discovery Rate (q) >0.22)). The PreHD cohort had slightly smaller putamen volumes (q=0.03), but this did not appear closely related to predicted years to onset. There were no group differences in other brain imaging measures (q>0.16). CSF and plasma neurofilament light (NfL) (q<0.0001 and q=0.01) and YKL-40 (q=0.03) were elevated in this far from onset preHD cohort. NfL elevations were more likely in individuals closer to expected clinical onset.

Conclusion: With normal brain function but with sensitive measures of neurodegeneration starting to rise, this stage of preHD ~24 years from predicted onset represents an optimal time to initiate future disease-modifying prevention treatments. CSF NfL appears more sensitive than plasma NfL to monitor treatment response. Although preHD had smaller putamen volumes, the small effect size and lack of association with years to onset would limit the utility of this measure in clinical trials at this stage. This is the earliest cohort yet studied in premanifest HD and interventions at this timepoint may offer the best prospect of delaying or preventing further neurodegeneration whilst function is intact.

Figure 1. Overview of assessments

Table 1 YAS Demographics

Figure 3. Volumetric imaging results

Figure 2. Radar plots of cognitive and neuropsychiatric results

Figure 4. Biofluid results

To cite this abstract in AMA style:

P. Zeun, R. Scahill, K. Osborne-Crowley, E. Johnson, S. Gregory, C. Parker, J. Lowe, A. Nair, C. O'Callaghan, C. Langley, M. Papoutsi, P. McColgan, C. Estevez-Fraga, K. Fayer, H. Wellington, F. Rodrigues, L. Byrne, A. Heselgrave, H. Hyare, C. Sampaio, H. Zetterberg, H. Zhang, E. Wild, G. Rees, T. Robbins, B. Sahakian, D. Langbehn, S. Tabrizi. Biological and Clinical Manifestations of Huntington’s disease in Gene Carriers Very Far from Predicted Onset: The Young Adult Study [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/biological-and-clinical-manifestations-of-huntingtons-disease-in-gene-carriers-very-far-from-predicted-onset-the-young-adult-study/. Accessed May 18, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/biological-and-clinical-manifestations-of-huntingtons-disease-in-gene-carriers-very-far-from-predicted-onset-the-young-adult-study/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley